CAR-T Cell Therapy for Refractory Non-Hodgkin Lymphoma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Refractory Non-Hodgkin Lymphoma+2 MoreCAR-T Cell Therapy - Biological
Eligibility
18 - 80
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test if a combination of CAR T-cell therapy, Mosunetuzumab, and Polatuzumab Vedotin can shrink tumors.

Eligible Conditions
  • Refractory Non-Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
  • Non-Hodgkin's Lymphoma, Relapsed

Treatment Effectiveness

Study Objectives

1 Primary · 7 Secondary · Reporting Duration: Up to 2 years

3 Months
Complete Response Rate
Up to 1 year
Minimal residual disease (MRD) negativity
Up to 2 years
Duration of Response (DoR)
Overall Survival (OS) Rate
Progression free survival (PFS) Rate
Up to 3 months
Overall Response Rate (ORR)
Up to 6 months
Toxicity Rate of CAR-T Cell Therapy: CRS Events
Toxicity Rate of CAR-T Cell Therapy: ICANS Events

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

Combination CAR-T Cell Therapy, Mosunetuzumab + Polatuzumab
1 of 1

Experimental Treatment

40 Total Participants · 1 Treatment Group

Primary Treatment: CAR-T Cell Therapy · No Placebo Group · Phase 2

Combination CAR-T Cell Therapy, Mosunetuzumab + PolatuzumabExperimental Group · 3 Interventions: CAR-T Cell Therapy, Polatuzumab, Mosunetuzumab · Intervention Types: Biological, Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mosunetuzumab
2020
Completed Phase 1
~30

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 2 years

Who is running the clinical trial?

Genentech, Inc.Industry Sponsor
1,497 Previous Clinical Trials
564,576 Total Patients Enrolled
Lazaros LekakisLead Sponsor
Lazaros Lekakis, MDPrincipal InvestigatorUniversity of Miami

Eligibility Criteria

Age 18 - 80 · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a high grade B cell lymphoma (HGBL), other than B-lymphoblastic lymphoma.
You have Mantle Cell lymphoma (MCL).
Relapsed/refractory Burkitt lymphoma (BL) patients are eligible for enrollment in this study.
You have a measurable lymphoma lesion or an extra-nodal lymphoma lesion ≥1.0 cm in the longest diameter.